Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2025-12-25 @ 4:58 AM
Ignite Modification Date:
2025-12-25 @ 4:58 AM
NCT ID:
NCT02069418
Eligibility Criteria:
Inclusion Criteria:
* age over superior to 18
* NSCLC proved by a histological biopsy
* EGFR mutation status known with no activating EGFR mutation
* indication of erlotinib therapy after at least one previous therapy
* patients who have signed an informed consent to participate in this study
* life expectancy exceeding 12 weeks
* WHO activity score between 0 and 2.
Exclusion Criteria:
* contraindication for the initiation of erlotinib
* refusal to sign the consent
* progressive inflammatory disease
* infection with the HIV virus
* other malignant disease
* life expectancy less than 12 weeks
* major adults protected by French law
Healthy Volunteers:
False
Sex:
ALL
Minimum Age:
18 Years
Study:
NCT02069418
Study Brief:
Protocol Section:
NCT02069418